Intangible Assets

6 Months Ended

Apr. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible Assets

Goodwill

(In millions)	CooperVision		CooperSurgical		Total
Balance at October 31, 2016	$	1,646.4	$	518.3	$	2,164.7
Net additions during the year ended October 31, 2017	28.6		94.4		123.0
Translation	60.7		6.4		67.1
Balance at October 31, 2017	1,735.7		619.1		2,354.8
Net additions during the six months ended April 30, 2018	36.8		31.6		68.4
Translation	34.1		3.8		37.9
Balance at April 30, 2018	$	1,806.6	$	654.5	$	2,461.1

We performed our annual impairment assessment in our third quarter of fiscal 2017 and 2016, and our analysis indicated that we had no impairment of goodwill. We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. We account for goodwill and evaluate our goodwill balances and test them for impairment in accordance with related accounting standards.

Other Intangible Assets

	April 30, 2018				October 31, 2017
(In millions)	Gross Carrying Amount		Accumulated Amortization & Translation		Gross Carrying Amount		Accumulated Amortization & Translation		Weighted Average Amortization Period (In years)
Trademarks	$	140.5	$	11.9	$	44.5	$	10.3	17
Composite intangible asset	1,061.9		35.4		—		—		15
Technology	407.9		186.5		428.8		173.2		11
Customer relationships	359.4		158.5		335.5		145.3		13
License and distribution rights and other	75.3		50.7		69.2		44.5		9
	2,045.0		$	443.0	878.0		$	373.3	14
Less: accumulated amortization and translation	443.0				373.3
Other intangible assets, net	$	1,602.0			$	504.7

The estimation of amortization expenses for fiscal 2018 to 2022 for our existing other intangible assets at April 30, 2018, are as follows:

Fiscal year	(In millions)
2018	$	145.4
2019	$	143.3
2020	$	133.0
2021	$	131.6
2022	$	129.5

In the second quarter of fiscal 2018, CooperSurgical recognized an impairment charge of $24.4 million on the intangible assets acquired from Recombine Inc. as the cash flows expected to be generated by this asset group over its estimated remaining life were not sufficient to recover its carrying value. CooperSurgical acquired Recombine Inc. in fiscal 2016, a clinical genetic testing company specializing in carrier screening. The intangible assets impaired consist of Technology, Trademark and Customer relationships.